IL33 and cancer: To determine whether IL-33-activated Tregs contributed to cancer development in HBV+DEN-treated mice, we subjected Foxp3Cre, ST2 flox/flox (TregST2CKO) mice in which ST2 was specifically deleted in Tregs to HBV+DEN liver carcinogenesis protocol (Fig. 1a).